Cerus Corporation (CERS) |
|
2.9 0.08 (2.84%)
|
03-24 16:00 |
|
Open: |
2.83 |
Pre. Close: |
2.82 |
|
High:
|
2.93 |
Low:
|
2.78 |
|
Volume:
|
1,082,033 |
Market Cap:
|
515(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:47 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.56  One year: 4.16 |
| Support: |
Support1: 2.62 Support2: 2.35 |
| Resistance: |
Resistance1: 3.05 Resistance2: 3.56 |
| Pivot: |
2.86 |
| Moving Average: |
MA(5): 2.88 MA(20): 2.85 
MA(100): 3.38 MA(250): 4.18 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 49 %D(3): 61 |
| RSI: |
RSI(14): 49.3 |
| 52-week: |
High: 5.94 Low: 2.35 |
| Average Vol(K): |
3-Month: 1,671 (K) 10-Days: 1,957 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CERS ] has closed below upper band by 37.8%. Bollinger Bands are 57.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.93 - 2.95 |
2.95 - 2.96 |
|
Low:
|
2.75 - 2.76 |
2.76 - 2.78 |
|
Close:
|
2.88 - 2.9 |
2.9 - 2.92 |
|
Company Description |
|
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California. |
Headline News |
Wed, 22 Mar 2023
Cerus (NASDAQ:CERS) Upgraded at StockNews.com - MarketBeat
Tue, 14 Mar 2023
Cerus (NASDAQ:CERS) has been upgraded by StockNews.com. - Best Stocks
Mon, 13 Mar 2023
Engineers Gate Manager LP Purchases 42432 Shares of Cerus Co ... - MarketBeat
Fri, 10 Mar 2023
‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks ... - TipRanks
Wed, 01 Mar 2023
Do Traders Think Cerus Corporation (CERS) Can Turn Around Wednesday? - InvestorsObserver
Wed, 15 Feb 2023
Cerus Corporation to Release Fourth Quarter and Full Year 2022 ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
178 (M) |
| Shares Float |
156 (M) |
|
% Held by Insiders
|
3.3 (%) |
|
% Held by Institutions
|
81.8 (%) |
|
Shares Short
|
7,680 (K) |
|
Shares Short P.Month
|
6,260 (K) |
Stock Financials |
|
EPS
|
-0.24 |
|
EPS Est Next Qtl
|
-0.16 |
|
EPS Est This Year
|
-0.64 |
|
EPS Est Next Year
|
-0.48 |
|
Book Value (p.s.)
|
0.37 |
|
Profit Margin (%)
|
-26.4 |
|
Operating Margin (%)
|
-21.1 |
|
Return on Assets (ttm)
|
-9.4 |
|
Return on Equity (ttm)
|
-55.6 |
|
Qtrly Rev. Growth
|
10.5 |
|
Gross Profit (p.s.)
|
0.49 |
|
Sales Per Share
|
0.91 |
|
EBITDA (p.s.)
|
-0.18 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-26 (M) |
|
Levered Free Cash Flow
|
-13 (M) |
Stock Valuations |
|
PE Ratio
|
-12.09 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
7.63 |
|
Price to Sales
|
3.17 |
|
Price to Cash Flow
|
-20.12 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
